Samsung BioLogics' First Trading Day - Blunders in Barron's Argument & Price Prediction
As reported by Barron's on Nov 5 ("Samsung BioLogics IPO: Too Expensive"), there are still some skeptical views on BioLogics' IPO valuation....
235 Views
One World, Two Stories
Celltrion's management continues to make very optimistic projections about Remsima's US sales in 2017 despite regulatory hurdles that will limit...
147 Views
SillaJen IPO Part 2 - Growth Potential & Appropriate Valuation Level
* In Part 2 (as below), I summarized the growth potential and appropriate valuation level of SillaJen.Apparently, not many people are doubtful...
257 Views
Korea National Pension Fund - Commitment to Buy 1 Trillion Won Worth of Small Cap Stocks in Korea
On October 26th, The Korea National Pension Fund (KNPF) announced that it will purchase 1 trillion won worth of small-mid cap stocks on the Korean...
180 Views
Some Actionable Ideas in the Biotechnology and Pharmaceutical Sector: October 31 Sector Update
Acadia Pharmaceuticals Inc (ACAD US), our portfolio company announced the initiation of a phase 2 study of Nuplazid in Alzheimer's related...
279 Views